Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of the American Chemical Society

• Publication date

  2017-06-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jacs.7b02694PMID 28570818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.

  2017cited by this paper
• A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

  2017cited by this paper
• Anatomy of RISC: how do small RNAs and chaperones activate Argonaute proteins?

  2016cited by this paper
• Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification

  2015cited by this paper
• Modulation of the RNA Interference Activity Using Central Mismatched siRNAs and Acyclic Threoninol Nucleic Acids (aTNA) Units

  2015cited by this paper
• Structural basis for microRNA targeting

  2014cited by this paper
• Enhancement of Stability and Activity of siRNA by Terminal Substitution with Serinol Nucleic Acid (SNA)

  2014cited by this paper
• Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.

  2014cited by this paper
• siRNA-optimized Modifications for Enhanced In Vivo Activity

  2012cited by this paper
• Designing chemically modified oligonucleotides for targeted gene silencing.

  2012cited by this paper
• Towards automated crystallographic structure refinement with phenix.refine

  2012cited by this paper
• The Crystal Structure of Human Argonaute2

  2012cited by this paper
• The structure of human argonaute-2 in complex with miR-20a.

  2012cited by this paper
• On the structure and dynamics of duplex GNA.

  2011cited by this paper
• Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs.

  2011cited by this paper
• Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo.

  2010cited by this paper
• Modulation of thermal stability can enhance the potency of siRNA

  2010cited by this paper
• Atomic resolution duplex structure of the simplified nucleic acid GNA.

  2010cited by this paper
• Improved phosphoramidite building blocks for the synthesis of the simplified nucleic acid GNA.

  2009cited by this paper
• Structural insights into RNA Processing by the Human RISC-Loading Complex

  2009cited by this paper
• A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity

  2009cited by this paper
• Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo

  2009cited by this paper
• Duplex Structure of a Minimal Nucleic Acid

  2008cited by this paper
• Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection

  2008cited by this paper
• Duplex Formation of the Simplified Nucleic Acid GNA

  2007cited by this paper
• Synthesis of Glycol Nucleic Acids

  2006cited by this paper
• Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA.

  2005cited by this paper
• A simple glycol nucleic acid.

  2005cited by this paper
• PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

  2004cited by this paper
• Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

  2004cited by this paper
• Argonaute2 Is the Catalytic Engine of Mammalian RNAi

  2004cited by this paper
• HKL2MAP: a graphical user interface for macromolecular phasing with SHELX programs

  2004cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Functional siRNAs and miRNAs exhibit strand bias.

  2003cited by this paper
• Substructure solution with SHELXD.

  2002cited by this paper
• Single-stranded antisense siRNAs guide target RNA cleavage in RNAi.

  2002cited by this paper
• Stability and structure of RNA duplexes containing isoguanosine and isocytidine.

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998cited by this paper
• Theoretical and Experimental Study of Isoguanine and Isocytosine: Base Pairing in an Expanded Genetic System

  1997cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Synthesis and evaluation of oligodeoxynucleotides containing acyclic nucleosides: introduction of three novel analogues and a summary.

  1995cited by this paper
• Sparse matrix sampling: a screening method for crystallization of proteins

  1991cited by this paper
• Aliphatic analogues of nucleotides: synthesis and affinity towards nucleases.

  1974cited by this paper
• Condensation polymerization of nucleotide analogues

  1972cited by this paper
• Synthesis of N-(2,3-dihydroxypropyl) derivatives of nucleic bases

  1971cited by this paper
• Electronic Reprint Biological Crystallography Phenix : a Comprehensive Python-based System for Macromolecular Structure Solution

  year unknowncited by this paper

• 2′-Ribose-modified nucleotides: A strategy for reducing off-target effects of oligonucleotide drugs

  2026cites this paper
• 3'-C-Extended TNA: De Novo Synthesis, Enhanced Exonuclease Resistance, and Functional siRNA 3'-Overhang Modifications Without Compromising Gene Silencing.

  2025cites this paper
• siRNA Features—Automated Machine Learning of 3D Molecular Fingerprints and Structures for Therapeutic Off-Target Data

  2025cites this paper
• The XNA alphabet

  2025cites this paper
• Chemical Modifications in Nucleic Acid Therapeutics.

  2025cites this paper
• Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

  2025cites this paper
• C16-siRNAs in Focus: Development of ALN-APP, a Promising RNAi-Based Therapeutic for Alzheimer’s Disease

  2025cites this paper
• Modified unlocked nucleic acid (MUNA) mitigates off-target effects of small interfering RNAs

  2025cites this paper
• Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates

  2025cites this paper
• Advances in structural-guided modifications of siRNA.

  2024cites this paper
• Oligonucleotide therapeutics and their chemical modification strategies for clinical applications

  2024influential citation
• N3-Methyluridine and 2'-O-Alkyl/2'-Fluoro-N3-methyluridine functionalized nucleic acids improve nuclease resistance while maintaining duplex geometry.

  2024cites this paper
• Chemically Modified Platforms for Better RNA Therapeutics.

  2024cites this paper
• The guide RNA sequence dictates the slicing kinetics and conformational dynamics of the Argonaute silencing complex

  2024cites this paper
• The structural basis for RNA slicing by human Argonaute2

  2024cites this paper
• High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination

  2024cites this paper
• Structural basis for gene silencing by siRNAs in humans

  2024cites this paper
• Improving the potency prediction for chemically modified siRNAs through insights from molecular modeling of individual sequence positions

  2024cites this paper
• Hepatocyte targeting via the asialoglycoprotein receptor

  2024cites this paper
• Investigating the Effect of Chemical Modifications on the Ribose Sugar Conformation, Watson-Crick Base Pairing, and Intrastrand Stacking Interactions: A Theoretical Approach.

  2024cites this paper
• The guide-RNA sequence dictates the slicing kinetics and conformational dynamics of the Argonaute silencing complex.

  2024cites this paper
• Chemistry, structure and function of approved oligonucleotide therapeutics

  2023cites this paper
• Two Birds with One Stone: A Novel Dithiomaleimide-Based GalNAc-siRNA Conjugate Enabling Good siRNA Delivery and Traceability

  2023cites this paper
• RNA-based nanomedicines and their clinical applications

  2023cites this paper
• Conformational Morphing by a DNA Analogue Featuring 7-Deazapurines and 5-Halogenpyrimidines and the Origins of Adenine-Tract Geometry.

  2023cites this paper
• Shorter Is Better: The α-(l)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs.

  2023cites this paper
• Long non-coding RNA-targeting therapeutics: discovery and development update

  2023cites this paper
• Synthesis and Structural Analysis of N3‐Methyluridine and 2’‐Alkoxy/Fluoro‐N3‐Methyluridine Nucleosides by Using NMR Spectroscopy, X‐Ray Crystallography, and Computational Methods

  2023cites this paper
• Development of Nucleic Acid Medicines Based on Chemical Technology.

  2023cites this paper
• Glycomimetics for the inhibition and modulation of lectins

  2023cites this paper
• Interdisciplinary advances reshape the delivery tools for effective NASH treatment

  2023cites this paper
• Functionalization of acyclic xenonucleic acid with modified nucleobases

  2023cites this paper
• Acyclic (S)-glycol nucleic acid (S-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency

  2023influential citation
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Therapeutic RNA-silencing oligonucleotides in metabolic diseases

  2022cites this paper
• 7,8-Dihydro-8-oxo-1,N6-ethenoadenine: an exclusively Hoogsteen-paired thymine mimic in DNA that induces A→T transversions in Escherichia coli

  2022cites this paper
• Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2

  2022cites this paper
• Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications

  2022cites this paper
• Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases

  2022cites this paper
• Evaluation of 3′-phosphate as a transient protecting group for controlled enzymatic synthesis of DNA and XNA oligonucleotides

  2022cites this paper
• Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates

  2022cites this paper
• From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Role of a “Magic” Methyl: 2′-Deoxy-2′-α-F-2′-β-C-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5′-Phosphate Mimics and Mitigation of Off-Target Effects

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Nucleic acid therapy in pediatric cancer.

  2022cites this paper
• Small Interfering RNAs Containing Dioxane- and Morpholino-Derived Nucleotide Analogues Show Improved Off-Target Profiles and Chirality-Dependent In Vivo Knock-Down.

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• Minireview The Nonclinical Disposition and Pharmacokinetic/ Pharmacodynamic Properties of N -Acetylgalactosamine – Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human S

  2022cites this paper
• siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs

  2021cites this paper
• Beyond ribose and phosphate: Selected nucleic acid modifications for structure–function investigations and therapeutic applications

  2021cites this paper
• The current landscape of nucleic acid therapeutics

  2021cites this paper
• The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human

  2021cites this paper
• Nonviral siRNA delivery systems for pancreatic cancer therapy

  2021cites this paper
• The development and improvement of ribonucleic acid therapy strategies

  2021cites this paper
• Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs

  2021influential citation
• Expanding the Reach of RNAi Therapeutics with Next Generation Lipophilic siRNA Conjugates

  2021cites this paper
• An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis

  2021influential citation
• Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity

  2021cites this paper
• Acyclic Nucleic Acids with Phosphodiester Linkages—Synthesis, Properties and Potential Applications

  2021cites this paper
• Chemical strategies for strand selection in short-interfering RNAs

  2021cites this paper
• Site-specific Incorporation of 2',5'-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides.

  2021cites this paper
• Development of siRNA Therapeutics for the Treatment of Liver Diseases.

  2021cites this paper
• Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs

  2021cites this paper
• Synthesis of 2′‐Fluorinated Northern Methanocarbacyclic (2′‐F‐NMC) Nucleosides and Their Incorporation Into Oligonucleotides

  2020cites this paper
• N-acetylgalactosamine (GalNAc)-conjugates: Delivering oligonucleotide drugs to the liver

  2020cites this paper
• Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

  2020cites this paper
• Emerging siRNA design principles and consequences for biotransformation and disposition in drug development.

  2020cites this paper
• Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo

  2020cites this paper
• Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc–siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease

  2020cites this paper
• Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents.

  2020cites this paper
• The current state and future directions of RNAi-based therapeutics

  2019cites this paper
• Synthesis and Biophysical Characterization of RNAs Containing 2'-Fluorinated Northern Methanocarbacyclic Nucleotides.

  2019cites this paper
• Re-Engineering RNA Molecules into Therapeutic Agents.

  2019cites this paper
• Current Development of siRNA Bioconjugates: From Research to the Clinic

  2019cites this paper
• In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters

  2019cites this paper
• The remarkable UV light invulnerability of thymine GNA dinucleotides.

  2019cites this paper
• GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

  2018cites this paper
• Chimeric XNA: An Unconventional Design for Orthogonal Informational Systems.

  2018cites this paper
• Structural basis for the synergy of 4′- and 2′-modifications on siRNA nuclease resistance, thermal stability and RNAi activity

  2018cites this paper
• RNA octamer containing 2'-OMe, 4'- Cbeta-OMe U.

  2018cites this paper
• P-Stereodefined phosphorothioate analogs of glycol nucleic acids—synthesis and structural properties

  2018cites this paper
• Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity

  2018cites this paper